title: Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
abstract: OBJECTIVE
  We aimed to explore what impact miR-503 has on the prognosis of patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Cancer and matched non-malignant lung tissue specimens were collected from 109 patients who underwent surgery in Tanisha Hospital from Jun 2006 to July 2013. Overall survival (OS) curves were analyzed using the Lapland-Meier method, and the differences were examined using log-rank tests. Cox proportional- hazards regression analysis was applied in order to estimate univariate and multivariate hazard ratios for OS.
  
  
  RESULTS
  The relative expression of miR-503 in NSCLC tissues (0.366±0.130) was significantly lower than that in matched noncancerous lung tissues (1.667±1.047, P<0.01). Statistically significant association was observed between miR-503 expression and lymphatic invasion (P=0.005), distant metastasis (P=0.002), TNM stage (P=0.008), and tumor grade (P=0.043). Lapland Meier analysis clearly illustrated that the patients with the lower expression of miR-503 had a worse outcome compared to patients with higher miR-503 expression (P=0.004). Furthermore, multivariate analysis revealed that miR-503 expression level was an independent prognostic factor for overall survival (HR=3.992, 95% CI: 2.276-9.872; P=0.018) in NSCLC.
  
  
  CONCLUSIONS
  In patients with NSCLC, low miR-503 expression is an independent prognostic factor.
authors.affiliation: Department of Medical Oncology, Yantaishan Hospital Yantai, Shandong, P.R. China.
authors.forename: Lei
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Yantaishan Hospital Yantai, Shandong, P.R. China.
authors.forename: Weiqing
authors.initials: W
authors.lastname: Qu
authors.affiliation: Department of Medical Oncology, Yantaishan Hospital Yantai, Shandong, P.R. China.
authors.forename: Zhaokun
authors.initials: Z
authors.lastname: Zhong
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D002681:China; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C545473:MIRN503 microRNA, human; D035683:MicroRNAs
keywords: NSCLC; biomarker; miR-503; micro RNA; prognosis